Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01784133 · ClinicalTrials.gov registry record · Phase 2
A Twelve Week Safety and Efficacy Study in Rosacea
A Phase 2 study of Papulopustular Rosacea, sponsored by Maruho Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 17
- Study locations
NCT01784133 is a Phase 2 study of Papulopustular Rosacea that has completed, run by Maruho Co.. The registered enrollment target is 240 participants, roughly in line with the 258-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target. The trial reports 17 study locations across 13 states.
The verdict
NCT01784133, a Phase 2 study of Papulopustular Rosacea, has completed, sponsored by Maruho Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to evaluate th safety and efficacy of one-daily topical application of CLS001 low, mid and high dose compared to vehicle gel in subjects with papulopustular rosacea.
Conditions Studied
Interventions
- DRUG placebo
- DRUG omiganan
Study Locations (17)
Florida
- Skin Care Research, Inc - Boca Raton
- Dunedin Research Specialists - Dunedin
- North Florida Dermatology Associates - Jacksonville
New York
- Rochester General Medical Group Center for Dermatology at Linden Oaks - Rochester
- Derm Research Center of NY Inc. - Stoney Brook
Tennessee
- TriCities Skin and Cancer - Johnson City
- Tennessee Clinical Research Center - Nashville
Alabama
- Radiant Research Inc. - Birmingham
California
- ATS Clinical Research - Santa Monica
Connecticut
- The Savin Center, PC - New Haven
Indiana
- Dawes Fretzin Clinical Research Group - Indianapolis
Michigan
- Grekin Skin Institute - Warren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01784133
The ClinicalTrials.gov registry entry for NCT01784133 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 258-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target. The listed sponsor is Maruho Co., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Papulopustular Rosacea appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01784133 reports 17 study locations spanning 13 distinct geographic areas - top geographies include Florida, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01784133 about?
NCT01784133 is a clinical study titled "A Twelve Week Safety and Efficacy Study in Rosacea". The purpose of this study is to evaluate th safety and efficacy of one-daily topical application of CLS001 low, mid and high dose compared to vehicle gel in subjects with papulopustular rosacea.
What is the current status of trial NCT01784133?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2013-03.
What conditions does trial NCT01784133 study?
This clinical trial studies the following conditions: Papulopustular Rosacea.
What interventions are being tested in trial NCT01784133?
The interventions under investigation include: placebo (DRUG), omiganan (DRUG).
Who is sponsoring clinical trial NCT01784133?
This trial is sponsored by Maruho Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01784133 being conducted?
This trial has 17 study locations across Alabama, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
RECRUITING · Phase 2
-
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
COMPLETED · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
COMPLETED · Phase 3
-
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
COMPLETED · NA
-
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.